ArticlePlant molecular biology2011
Functional analysis and expression profiling of HcrVf1 and HcrVf2 for development of scab resistant cisgenic and intragenic apples.
Article in Plant molecular biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 126 citations in OpenAlex.
- Article
- Fine-mapping, candidate gene identification, and marker development for the apple scab resistance gene Rvi2.Journal of experimental botany · 2026Article
- Real-time identification and quantification of apple scab on fruit in preharvest and postharvest conditions using YOLO11: a deep learning approach.Plant methods · 2026Article
- Inducible MdAGG lectins in apple immunity toward fire blight: CRISPR/Cas9 validation and their potential for intragenesis approaches.Horticulture research · 2026Article
- Marker-assisted screening of resistance to fire blight, powdery mildew, and apple scab in local apple varieties from Uzbekistan.PloS one · 2026Article
- The evolving landscape of precise DNA insertion in plants.Nature communications · 2025Review
- Rvi6-mediated defense mechanisms against apple scab.BMC plant biology · 2025Article
- The Hansen's baccata #2 gene Rvi12_Cd5 confers scab resistance to the susceptible apple cultivar "Gala Galaxy".The Plant journal : for cell and molecular biology · 2025Article
- Overview on Current Selectable Marker Systems and Novel Marker Free Approaches in Fruit Tree Genetic Engineering.International journal of molecular sciences · 2024Review
- The Transcriptional Landscape of Berry Skin in Red and White PIWI ("Pilzwiderstandsfähig") Grapevines Possessing QTLs for Partial Resistance to Downy and Powdery Mildews.Plants (Basel, Switzerland) · 2024Article
- Phenotyping, genetics, and "-omics" approaches to unravel and introgress enhanced resistance against apple scab (Horticulture research · 2024Article
- Chromosome-level phased genome assembly of "Antonovka" identified candidate apple scab-resistance genes highly homologous to HcrVf2 and HcrVf1 on linkage group 1.G3 (Bethesda, Md.) · 2023Article
- From Transgenesis to Genome Editing in Crop Improvement: Applications, Marketing, and Legal Issues.International journal of molecular sciences · 2023Review
- Cisgenics and intragenics: boon or bane for crop improvement.Frontiers in plant science · 2023Review
- Comparative transcriptomics unravels new genes imparting scab resistance in apple (Malus x domestica Borkh.).Functional & integrative genomics · 2022Article
- An Erwinia amylovora inducible promoter for improvement of apple fire blight resistance.Plant cell reports · 2022Article
- Genetic Improvement of Wheat for Drought Tolerance: Progress, Challenges and Opportunities.Plants (Basel, Switzerland) · 2022Review
- GrapevineBiomolecules · 2022Article
- Recent Developments and Strategies for the Application ofFrontiers in plant science · 2022Review
- The Intragenesis and Synthetic Biology Approach towards Accelerating Genetic Gains on Strawberry: Development of New Tools to Improve Fruit Quality and Resistance to Pathogens.Plants (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apple scab resistance genes, HcrVf1 and HcrVf2, were isolated including their native promoter, coding and terminator sequences. Two fragment lengths (short and long) of the native gene promoters and the strong apple rubisco gene promoter (P(MdRbc)) were used for both HcrVf genes to test their effect on expression and phenotype. The scab susceptible cultivar 'Gala' was used for plant transformations and after selection of transformants, they were micrografted onto apple seedling rootstocks for scab disease tests. Apple transformants were also tested for HcrVf expression by quantitative RT-PCR (qRT-PCR). For HcrVf1 the long native promoter gave significantly higher expression that the short one; in case of HcrVf2 the difference between the two was not significant. The apple rubisco gene promoter proved to give the highest expression of both HcrVf1 and HcrVf2. The top four expanding leaves were used initially for inoculation with monoconidial isolate EU-B05 which belongs to race 1 of V. inaequalis. Later six other V. inaequalis isolates were used to study the resistance spectra of the individual HcrVf genes. The scab disease assays showed that HcrVf1 did not give resistance against any of the isolates tested regardless of the expression level. The HcrVf2 gene appeared to be the only functional gene for resistance against Vf avirulent isolates of V. inaequalis. HcrVf2 did not provide any resistance to Vf virulent strains, even not in case of overexpression. In conclusion, transformants carrying the apple-derived HcrVf2 gene in a cisgenic as well as in an intragenic configuration were able to reach scab resistance levels comparable to the Vf resistant control cultivar obtained by classical breeding, cv. 'Santana'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.